Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting

05 Aug 2016

• By Derrick Gingery

Related Content

Biosimilar Manufacturer Reliability Is Key To Market Uptake, Amgen Says

19 Apr 2016

Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action

15 Jul 2016

Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?

22 Jul 2016

Biosimilars: Does FDA Caution Make Advisory Committee A Rubber Stamp?

10 Jul 2016

Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway

13 Jul 2016

Biosimilar Labeling: Should FDA Just Throw Up Its Hands And Finalize Guidance?

05 Aug 2016

AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims

05 Aug 2016

Related Companies

AbbVie Inc.

Amgen, Inc.

Novartis AG

Additional Topics

United States Biosimilars Drug Review Regulation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.